8B4A5C0E-9F4C-4E4D-B12E-B97666C99707
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 50.59132720105124
- age_years
- 28
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.565
- MYC_TARGETS_V1+0.514
- TGF_BETA_SIGNALING+0.443
- NOTCH_SIGNALING+0.442
- ALLOGRAFT_REJECTION+0.441
- UNFOLDED_PROTEIN_RESPONSE+0.433
- G2M_CHECKPOINT+0.430
- PROTEIN_SECRETION+0.397
- IL6_JAK_STAT3_SIGNALING+0.392
- E2F_TARGETS+0.382
Top 10 suppressed
- KRAS_SIGNALING_DN-0.408
- PANCREAS_BETA_CELLS-0.378
- MYOGENESIS-0.285
- SPERMATOGENESIS-0.223
- ESTROGEN_RESPONSE_LATE-0.116
- HYPOXIA-0.068
- XENOBIOTIC_METABOLISM-0.033
- COAGULATION-0.024
- APICAL_JUNCTION-0.023
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.003
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | E6AA40DA-9AB7-478B-B46B-827F9AFE52D1 | — | — | 0.951 |
| 2 | C8955D29-D8EE-4F68-AEAC-CE1B838B22BF | — | — | 0.938 |
| 3 | 0108A1FA-9CBF-4CF6-8981-7FB39C39B335 | — | — | 0.935 |
| 4 | 15838786-D895-4F63-88A9-BDE627AE7958 | — | — | 0.920 |
| 5 | 4880B586-BA92-48B2-A233-5C245D2E31C0 | — | — | 0.917 |
| 6 | AB522ACF-5D84-41B0-9671-CE2511EBD94F | — | — | 0.915 |
| 7 | 0F8BE394-BA6A-401C-87D0-9B3CF50FB0C8 | — | — | 0.915 |
| 8 | B66ECF23-8CB2-4C95-8E3D-AA63A494F4A0 | — | — | 0.915 |
| 9 | 67B2F9CD-759E-4300-8F4B-1B5C4F9E0B1C | — | — | 0.912 |
| 10 | C9A30C14-5D3E-47BA-8647-DFD49FD0E112 | — | — | 0.911 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.565 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.514 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.443 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.442 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.441 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.433 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.430 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.397 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.392 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.382 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.369 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.362 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.355 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.330 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| APOPTOSIS | 0.293 | Idelalisib | — uncovered |
| COMPLEMENT | 0.281 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.272 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.269 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.259 | Inavolisib | — uncovered |